Please login to the form below

Not currently logged in
Email:
Password:

Catalent appoints two board members

Jack Stahl and Rolf Classon to advise drug development, delivery and supply company
catalent-rolf-classon

Catalent has named two experienced healthcare figures to its board of directors.

Jack Stahl, former CEO of cosmetics firms Revlon, and Rolf Classon, former chairman at Bayer Healthcare, will use to their experience to advise Catalent, a leading player in providing drug development, delivery and supply services to pharma companies.

Stahl headed Revlon from 2002 to 2006 following a stint as chief operating officer at the Coca-Cola Company. He also serves on the Boards of Coty, Delhaize Group, and the US board of advisers of CVC Capital.

Classon served as chairman at Bayer Healthcare from 2002 until 2004 as part of a long career at Bayer that began in 1991. His roles at the German company included a seven-year spell as president of Bayer Diagnostics.

“We welcome both Jack and Rolf to our Board,” said John Chiminski, President and CEO, Catalent. “Both are senior healthcare executives, with a wealth of knowledge and experience within the sector.”

20th August 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics